China’s mAb and ADC licensing was 3xUS’s in 2024 — will trade tensions slow it?
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug…
Analyst Comment
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF
ATS 2025: Anti–IL-5 therapy cuts exacerbations in coexisting COPD and asthma patients
ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF care
ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despite CB
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
Five years, one approval: Europe’s slow march on Alzheimer’s treatments
